Qiagen (QGEN) AI Stock Analysis

• Market Cap: $10.47B
• Dividend Yield: 2.73%
• Average Volume (3M): 1.31M
• Price to Earnings (P/E): 115.8
• Beta (1Y): 0.73
• Revenue Growth: 3.31%
• EPS Growth: -72.63%
• Country: US
• Employees: 5,700
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 0.55
• Shares Outstanding: 216,556,000
• 10 Day Avg. Volume: 1,370,944
• 30 Day Avg. Volume: 1,306,130
• PEG Ratio: 6.90
• Price to Book (P/B): 3.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 20.13
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 1.38
• Enterprise Value/Gross Profit: 10.88
• Enterprise Value/Ebitda: 7.70
• 1Y Price Target: $50.71
• Price Target Upside: 4.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 14

• Rating: 72 Outperform
• Price Target: $53.00 ▲(9.64%Upside)

Qiagen's strong earnings performance and robust financial health are significant positive factors, indicating stability and growth potential. However, the high P/E ratio and overbought technical indicators suggest caution. Continued focus on strategic initiatives and overcoming challenges in key markets will be crucial for sustaining growth.

Positive Factors

Capital Allocation

Qiagen is planning its first-ever dividend and a $500 million share buyback, indicating a strong capital allocation strategy.

Management Effectiveness

The management team has been effective in managing continued revenue growth and improving profitability despite challenges in the sector.

Strategic Acquisitions

The acquisition of Genoox enhances Qiagen's clinical offering for small and mid-sized labs by unlocking cloud-based AI functionality.

Negative Factors

Core Growth Challenges

Core growth in the genomics and NGS segment declined and was below expectations, reflecting challenges in some areas.

Growth Uncertainty

There is a need for greater confidence in the durability of top-line growth in the latter half of 2025 and into 2026 before considering an upgrade in stock rating.

Product Launch Delays

Sample technologies experienced a decline in core growth due to ongoing instrument softness ahead of new product launches.

Qiagen Business Overview & Revenue Model

Company Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

How the Company Makes Money

Qiagen generates revenue through the sale of its comprehensive portfolio of products and services tailored for molecular testing and diagnostics. The company's revenue model is primarily based on selling consumables such as reagents, test kits, and cartridges, which are used in sample preparation and analysis workflows. Additionally, Qiagen earns significant income from its instruments, which are designed to automate laboratory processes and improve efficiency. The company also provides bioinformatics software and services that enhance data analysis capabilities for its users. Key revenue streams include direct sales to laboratories, hospitals, and research institutions, as well as strategic partnerships and collaborations with pharmaceutical and biotechnology companies. Qiagen's position in the market is strengthened by its continuous investment in research and development, enabling it to innovate and expand its product offerings in response to the evolving needs of its customers.

Qiagen Financial Statement Overview

Summary

Qiagen demonstrates stable financial health with strong cash flow management and a balanced capital structure. While revenue and profit margins face industry pressures, the company's operational efficiency and sound balance sheet provide a firm foundation for future growth. Continued focus on improving profitability and maintaining cash flow strength will be key to enhancing financial performance.

Income Statement

Qiagen's TTM revenue of $2.00 billion is slightly higher than the previous annual revenue of $1.98 billion, indicating modest growth. The gross profit margin is 50.0%, showing solid profitability, although it's a decline from past years. The net profit margin stands at 4.7%, which is relatively low but consistent with industry standards in challenging periods. EBIT and EBITDA margins are 5.9% and 18.6%, respectively, suggesting stable operational efficiency despite fluctuations in EBIT over recent years.

Balance Sheet

The debt-to-equity ratio is 0.41, indicating a solid capital structure with manageable debt levels. Return on Equity (ROE) is a modest 2.7%, reflecting challenges in generating strong returns on equity, partially due to reduced profitability. The equity ratio is a healthy 61.5%, showcasing a strong reliance on equity financing and solid asset backing, which bolsters financial stability.

Cash Flow

The TTM operating cash flow to net income ratio is robust at 7.26, indicating efficient cash conversion from profits. Free cash flow remains strong at $503 million, with a free cash flow to net income ratio of 5.37, highlighting effective cash management and investment capacity. Free cash flow growth is steady, reinforcing cash flow resilience even as net income fluctuates.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.00B	1.98B	1.97B	2.14B	2.25B	1.87B
Gross Profit	1.00B	1.32B	1.23B	1.38B	1.45B	1.23B
EBITDA	372.10M	368.26M	688.55M	779.36M	895.24M	715.80M
Net Income	93.68M	83.59M	341.30M	423.21M	512.60M	73.64M
Balance Sheet
Total Assets	5.55B	5.69B	6.12B	6.29B	6.15B	5.97B
Cash, Cash Equivalents and Short-Term Investments	963.45M	1.15B	1.06B	1.42B	1.07B	714.25M
Total Debt	1.41B	1.42B	1.61B	1.88B	1.96B	2.03B
Total Liabilities	2.14B	2.12B	2.31B	2.82B	3.05B	3.49B
Stockholders Equity	3.41B	3.57B	3.81B	3.47B	3.10B	2.48B
Cash Flow
Free Cash Flow	503.07M	506.38M	296.65M	565.93M	432.47M	188.03M
Operating Cash Flow	680.21M	673.55M	459.45M	715.26M	639.00M	492.27M
Investing Cash Flow	-135.58M	-249.23M	-87.66M	-726.76M	-202.43M	-453.29M
Financing Cash Flow	-417.51M	-422.90M	-433.83M	-125.80M	-150.37M	-74.32M

Qiagen Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 48.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QGEN, the sentiment is Positive. The current price of 48.34 is above the 20-day moving average (MA) of 46.90, above the 50-day MA of 44.42, and above the 200-day MA of 42.91, indicating a bullish trend. The MACD of 1.12 indicates Negative momentum. The RSI at 70.19 is Negative, neither overbought nor oversold. The STOCH value of 82.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QGEN.

Qiagen Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	79 Outperform	$19.75B	22.36	13.35%	1.81%	9.38%	6.43%
NTRA	73 Outperform	$22.09B	―	-18.66%	―	51.50%	53.23%
QGEN	72 Outperform	$10.47B	115.81	2.67%	2.73%	3.31%	-72.63%
RVTY	68 Neutral	$11.94B	40.06	3.82%	0.28%	1.62%	78.53%
Sector *	60 Neutral	HK$15.58B	5.65	-7.43%	4.32%	11.60%	-21.06%
ILMN	58 Neutral	$15.96B	―	-23.82%	―	-3.47%	25.55%
EXAS	54 Neutral	$10.07B	―	-36.89%	―	11.57%	-315.25%